CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer.
  
  OVERVIEW OF ACTIVITY
  The American Cancer Society estimates that 81,400 new cases of bladder cancer will be diagnosed in the United States in 2020 and 17,980 deaths will be attributable to this disease over that time. The disease is the fourth most common cancer in men in the United States and is 3 times as likely to be found in men than in women. Although bladder cancer is a heterogeneous collection of diseases, more than 90% of patients are diagnosed with its most common form, urothelial carcinoma. This activity will focus on the current and future management of urothelial carcinoma.
  
  LEARNING OBJECTIVES

  • Recall the recent FDA approval of anti-PD-1 antibody therapy for patients with high-risk non-muscle-invasive urothelial bladder cancer (UBC) that is unresponsive to BCG, and identify individuals who may be appropriate candidates for this approach in routine practice.
  • Compare and contrast the available clinical trial evidence with the use of first- and later-line immune checkpoint inhibitors for the treatment of metastatic UBC (mUBC) to determine the current utility of these agents in clinical practice.
  • Review available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated mUBC, and consider the potential role of this approach in routine practice.
  • Describe the frequency of fibroblast growth factor receptor (FGFR) abnormalities in patients with mUBC, and recognize the recent FDA approval of erdafitinib for individuals with susceptible FGFR3 or FGFR2 genetic alterations who have experienced disease progression during or after at least 1 line of prior platinum-containing chemotherapy.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings leading to the recent FDA approval of enfortumab vedotin for patients with previously treated mUBC in order to appropriately integrate this novel compound into nonresearch treatment algorithms.
  • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for mUBC, and counsel appropriately selected patients about participation in active research protocols.
  • Recall new data with other investigational agents and strategies demonstrating promising activity in UBC, and discuss ongoing trial opportunities with eligible patients.

  PHYSICIAN COMPETENCIES TO BE ADDRESSED
  Medical Knowledge and Patient Care
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Peter H O’Donnell, MD
  Associate Professor, Department of Medicine
  Section of Hematology/Oncology
  Genitourinary Oncology Program
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreement: Merck; Honoraria: Astellas, Atheneum Partners, FirstWord Publication, Genentech, a member of the Roche Group, Health Advances, Janssen Biotech Inc, Merck, OncLive, Seattle Genetics, Schlesinger Associates, The Dedham Group; Ownership Interest: Allergan, PrescriptIQ; Paid Travel: Astellas, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Seattle Genetics; Independent Safety and Monitoring Board: Janssen Biotech Inc, Nektar.
  
  Daniel P Petrylak, MD
  Professor of Internal Medicine (Medical Oncology) and Urology
  Yale University
  New Haven, Connecticut
  
  Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.
  
  Elizabeth R Plimack, MD, MS
  Chief, Division of Genitourinary Medical Oncology
  Director, Genitourinary Clinical Research
  Professor, Department of Hematology/Oncology
  Fox Chase Cancer Center
  Temple Health
  Philadelphia, Pennsylvania
  
  Advisory Committee: Bristol-Myers Squibb Company, Flatiron Health, Genentech, Merck, Seattle Genetics; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Pfizer Inc.
  
  Jonathan E Rosenberg, MD
  Chief, Genitourinary Medical Oncology Service
  Division of Solid Tumor Oncology
  Enno W Ercklentz Chair
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Fees, Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Mirati Therapeutics, Roche Laboratories Inc, Seattle Genetics; Consulting Agreements: Adicet Bio, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioClin/Rainier Therapeutics, Biotherapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Fortress Biotech, Genentech, GlaxoSmithKline, Janssen Biotech Inc, Merck, Mirati Therapeutics, Pharmacyclics LLC, an AbbVie Company, QED Therapeutics, Roche Laboratories Inc, Seattle Genetics, Sensei Biotherapeutics, Western Oncolytics; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Novartis, QED Therapeutics, Roche Laboratories Inc, Seattle Genetics; Honorarium: Chugai Pharmaceutical Co Ltd; Data and Safety Monitoring Board/Committee: BioClin/Rainier Therapeutics.
  
  Guru Sonpavde, MD
  Director, Bladder Cancer
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Bicycle Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, National Comprehensive Cancer Network, Novartis, Pfizer Inc, Sanofi Genzyme, Seattle Genetics; Research Support to Institution: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Merck, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Sanofi Genzyme; Travel Costs: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Speaking Fees: Physicians Education Resource (PER), OncLive, Research To Practice, Clinical Care Options; Writing Fees: UpToDate; Steering Committee of Trials: Astellas, Bavarian Nordic, Bristol-Myers Squibb Company, Debiopharm Group, QED Therapeutics, Seattle Genetics (all unpaid), and AstraZeneca Pharmaceuticals LP and Debiopharm Group (both paid); Consulting Agreements: AstraZeneca Pharmaceuticals LP, Merck; Data and Safety Monitoring Board/Committee: Boehringer Ingelheim Pharmaceuticals Inc.
  
  COURSE DIRECTOR/PANEL MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seattle Genetics, Genentech, a member of the Roche Group, and Merck.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: March 2020
  Expiration date: March 2021